Lung neuroendocrine tumors: Correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Collaud, Stéphane ^a   Tischler, Verena ^a   Atanassoff, Andrej ^a   Wiedl, Thomas ^a   Komminoth, Paul ^b   Oehlschlegel, Christian ^c   Weder, Walter ^a   Soltermann, Alex ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

AC; Atypical carcinoid; Cytosol; FISH; Fluorescence in situ hybridization; Herpes virus associated ubiquitin specific protease 7; IHC; Immunohistochemistry; Large cell neuroendocrine carcinoma; LCNEC; Lung NET; Lung neuroendocrine tumor; Nucleo cytosolic partitioning; Nucleus; PTEN; SCLC; Small cell lung carcinoma; Small ubiquitin related modifier protein 2 3; SUMO2 3; Sumoylation; TC; Tissue microarray; TMA; Typical carcinoid; Ubiquitinylation; USP7

Indexed keywords

CHROMOGRANIN A; DEUBIQUITINASE; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SUMO 2 PROTEIN; SUMO 3 PROTEIN; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1; UBIQUITIN SPECIFIC PROTEASE 7; UNCLASSIFIED DRUG; PTEN PROTEIN, HUMAN; SUMO PROTEIN; TP53 PROTEIN, HUMAN; UBIQUITIN THIOLESTERASE; USP7 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CARCINOID; CELL COMPARTMENTALIZATION; CELL NUCLEUS; CYTOSOL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG NEUROENDOCRINE TUMOR; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PROTEIN EXPRESSION; SMALL CELL LUNG CANCER; SUMOYLATION; TISSUE MICROARRAY; TUMOR VOLUME; UBIQUITINATION; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEUS; CYTOSOL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN THIOLESTERASE; UBIQUITINATION; YOUNG ADULT;

EID: 84928717860     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1084-5     Document Type: Article

References (51)

1. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res. 2010;70(10):3877-83.
2. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44(10):1104-10.
3. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943-7.
4. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010;42(5):454-8.
5. Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci. 2012;125(Pt 20):4687-92.
6. Hopkins BD, Fine B, Steinbach N, Dendy M, Rapp Z, Shaw J, et al. A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science. 2013;341(6144):399-402.
7. Correia NC, Girio A, Antunes I, Martins LR, Barata JT. The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer. 2014;50(1):216-25.
8. Pallares J, Bussaglia E, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol. 2005;18(5):719-27.
9. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol. 2000;157(4):1097-103.
10. Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23(4):575-87.
11. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128(1):157-70.
12. Choi BH, Chen Y, Dai W. Chromatin PTEN is involved in DNA damage response partly through regulating Rad52 sumoylation. Cell Cycle. 2013;12(21):3442-7.
13. Lehman JA, Waning DL, Batuello CN, Cipriano R, Kadakia MP, Mayo LD. Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress. J Biol Chem. 2011;286(42):36631-40.
14. Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell. 2011;144(2):187-99.
15. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283-96.
16. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007;128(1):129-39.
17. Howitt J, Lackovic J, Low LH, Naguib A, Macintyre A, Goh CP, et al. Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia. J Cell Biol. 2012;196(1):29-36.
18. Jung S, Li C, Jeong D, Lee S, Ohk J, Park M, et al. Oncogenic function of p34SEI-1 via NEDD41mediated PTEN ubiquitination/degradation and activation of the PI3K/AKT pathway. Int J Oncol. 2013;43(5):1587-95.
19. Hong SW, Moon JH, Kim JS, Shin JS, Jung KA, Lee WK, et al. p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN. Cell Death Differ. 2014;21(1):146-60.
20. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007;128(1):141-56.
21. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J, et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature. 2008;455(7214):813-7.
22. Faesen AC, Dirac AM, Shanmugham A, Ovaa H, Perrakis A, Sixma TK. Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. Mol Cell. 2011;44(1):147-59.
23. Zhang J, Zhang P, Wei Y, Piao HL, Wang W, Maddika S, et al. Deubiquitylation and stabilization of PTEN by USP13. Nat Cell Biol. 2013;15(12):1486-94.
24. Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T, et al. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun. 2012;3:911.
25. Gonzalez-Santamaria J, Campagna M, Ortega-Molina A, Marcos-Villar L, de la Cruz-Herrera CF, Gonzalez D, et al. Regulation of the tumor suppressor PTEN by SUMO. Cell Death Dis. 2012;3:e393.
26. Bassi C, Ho J, Srikumar T, Dowling RJ, Gorrini C, Miller SJ, et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science. 2013;341(6144):395-9.
27. Wang W, Chen Y, Wang S, Hu N, Cao Z, Tong T, et al. PIASxalpha enhances SUMO1 modification of PTEN as a SUMO E3 ligase. J Biol Chem. 2014;289(6):3217-30.
28. Hickey CM, Wilson NR, Hochstrasser M. Function and regulation of SUMO proteases. Nat Rev Mol Cell Biol. 2012;13(12):755-66.
29. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol. 2000;156(5):1693-700.
30. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999;155(4):1253-60.
31. Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol. 2012;31(1):48-56.
32. Carvalho KC, Maia BM, Omae SV, Rocha AA, Covizzi LP, Vassallo J, et al. Best practice for PTEN gene and protein assessment in anatomic pathology. Acta Histochem. 2014;116(1):25-31.
33. Maiques O, Santacana M, Valls J, Pallares J, Mirantes C, Gatius S, et al. Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues. Hum Pathol. 2014;45(3):522-32.
34. Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C, Vogelstein B. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature. 2004;428(6982):1. p following 486.
35. Becker K, Marchenko ND, Palacios G, Moll UM. A role of HAUSP in tumor suppression in a human colon carcinoma xenograft model. Cell Cycle. 2008;7(9):1205-13.
36. Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, et al. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res. 2010;16(21):5244-51.
37. Kavela S, Shinde SR, Ratheesh R, Viswakalyan K, Bashyam MD, Gowrishankar S, et al. PNUTS functions as a proto-oncogene by sequestering PTEN. Cancer Res. 2013;73(1):205-14.
38. Andres-Pons A, Gil A, Oliver MD, Sotelo NS, Pulido R. Cytoplasmic p27Kip1 counteracts the pro-apoptotic function of the open conformation of PTEN by retention and destabilization of PTEN outside of the nucleus. Cell Signal. 2012;24(2):577-87.
39. Chung JH, Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res. 2005;65(18):8096-100.
40. Da Silva-Ferrada E, Xolalpa W, Lang V, Aillet F, Martin-Ruiz I, de la Cruz-Herrera CF, et al. Analysis of SUMOylated proteins using SUMO-traps. Sci Rep. 2013;3:1690.
41. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, et al. Regulation of PTEN transcription by p53. Mol Cell. 2001;8(2):317-25.
42. Tang Y, Eng C. p53 down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction. Cancer Res. 2006;66(12):6139-48.
43. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98(20):11598-603.
44. Chu EC, Tarnawski AS. PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit. 2004;10(10):RA235-241.
45. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer. 2004;4(2):106-17.
46. Fata JE, Debnath S, Jenkins Jr EC, Fournier MV. Nongenomic Mechanisms of PTEN Regulation. International journal of cell biology. 2012;2012:379685.
47. Liu F, Wagner S, Campbell RB, Nickerson JA, Schiffer CA, Ross AH. PTEN enters the nucleus by diffusion. J Cell Biochem. 2005;96(2):221-34.
48. Gil A, Andres-Pons A, Fernandez E, Valiente M, Torres J, Cervera J, et al. Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell. 2006;17(9):4002-13.
49. Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA. Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene. 2003;22(47):7458-67.
50. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet. 2004;363(9411):775-81.
51. Leslie NR, Brunton VG. Cell biology. Where is PTEN? Science. 2013;341(6144):355-6.